Abstract:Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the accumulation of Lewy bodies and loss of dopaminergic neurons in the substantia nigra pars compacta (SNpC). MPTP is widely used to generate murine PD model. In addition to classical motor disorders, PD patients usually have non-motor symptoms related to autonomic impairment, which precedes decades before the motor dysfunction. This study’s objective is to examine the effects of MPTP on noradrenergic neurons in the hindbrain, thereby on the cardiovascular function in mice. Adult mice received 10 mg/kg/day of MPTP (4 consecutive days) to generate PD model. Systolic blood pressure was measured by tail cuff system in conscious mice, and baroreflex sensitivity was evaluated by heart rate alteration in response to a transient increase or decrease in blood pressure induced by intravenous infusion of phenylalanine (PE) or sodium nitroprusside (SNP) in anesthetized condition, respectively. Baseline heart rate and heart rate variability were analyzed in both sham and MPTP-treated mice. Dopamine, norepinephrine, and related metabolites in the plasma and brain tissues including SNpC, locus coeruleus (LC), rostroventrolateral medulla (RVLM), and nucleus tractus solitarii (NTS) were measured by liquid chromatography-mass spectrometry (LC-MS). Tyrosine hydroxylase-positive (TH + ) neurons in above nuclei were quantified by immunoreactivities. We found that in addition to the loss of TH + neurons in SNpC, MPTP treatment induced a dramatic reduction of TH + cell counts in the LC, RVLM, and NTS. These are associated with significant decreases of dopamine, norepinephrine, and epinephrine in above nuclei. Meanwhile, MPTP induced a lasting effect of baroreflex desensitization, tachycardia, and decreased heart rate variability compared to the sham mice. Notably, MPTP treatment elevated sympathetic outflow and suppressed parasympathetic tonicity according to the heart rate power spectrum analysis. Our results indicate that the loss of TH + neurons in the brainstem by MPTP treatment led to impaired autonomic cardiovascular function. These results suggest that MPTP treatment can be used to study the autonomic dysfunction in murine model.

Blocking of canonical Notch signaling in dopaminergic neurons prevents its loss induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

MPTP-Induced Impairment of Cardiovascular Function

Depletion of Canonical Wnt Signaling Components Has a Neuroprotective Effect on Midbrain Dopaminergic Neurons in an MPTP-induced Mouse Model of Parkinson’s Disease

Myeloid-specific blockade of notch signaling alleviates dopaminergic neurodegeneration in Parkinson's disease by dominantly regulating resident microglia activation through NF-κB signaling

NRSF/REST Neuronal Deficient Mice Are More Vulnerable to the Neurotoxin MPTP

Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopamine neuronal damage in mouse model of Parkinson's disease

Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease

Effects of ERK1/2 signal pathway on COX-2,PGE2 expression in subacute MPTP-induced mouse model of Parkinson's disease

Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson's disease

RESP18 deficiency has protective effects in dopaminergic neurons in an MPTP mouse model of Parkinson's disease.

Loss of RAB39B Does Not Alter MPTP-induced Parkinson’s Disease-Like Phenotypes in Mice

Changes of heme oxygenase-1 expression in the nigrostriatal system of MPTP-treated SAMP8 mouse]

Damage to the Nigrostriatal System in the Mptp-Treated Samp8 Mouse

Study of Apoptosis Pattern of Dopaminergic Neurons and Neuroprotective Effect of Nicotine in MPTP Mouse Model

CXCR4 knockout induces neuropathological changes in the MPTP-lesioned model of Parkinson's disease

Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum.

Ketogenic Diet Affects Substantia Nigra TH, Bcl-2 and Caspase-3 Gene Expressions in Mouse Models with 1-Methyl-4-phenyl 1,2,3,6 Tetrahydropyridine-Induced PD

Nurr1 Downregulation is Caused by CREB Inactivation in a Parkinson’s Disease Mouse Model

Overexpression of Parkin Ameliorates Dopaminergic Neurodegeneration Induced by 1- Methyl-4-phenyl-1,2,3,6-tetrahydropyridine in Mice.

JNK-mediated Microglial DICER Degradation Potentiates Inflammatory Responses to Induce Dopaminergic Neuron Loss